List of Tables
Table 1. Global Radioligand Therapy Drugs for Cancer Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Radioligand Therapy Drugs for Cancer Market Value by Targeted Ligands (US$ Million), 2025 vs 2032
Table 3. Global Radioligand Therapy Drugs for Cancer Market Value by Radionuclides (US$ Million), 2025 vs 2032
Table 4. Global Radioligand Therapy Drugs for Cancer Market Value by Application (US$ Million), 2025 vs 2032
Table 5. Global Radioligand Therapy Drugs for Cancer Market Competitive Situation by Manufacturers in 2025
Table 6. Global Radioligand Therapy Drugs for Cancer Sales (K Units) of Key Manufacturers (2021–2026)
Table 7. Global Radioligand Therapy Drugs for Cancer Sales Market Share by Manufacturers (2021–2026)
Table 8. Global Radioligand Therapy Drugs for Cancer Revenue (US$ Million) by Manufacturers (2021–2026)
Table 9. Global Radioligand Therapy Drugs for Cancer Revenue Share by Manufacturers (2021–2026)
Table 10. Global Market Radioligand Therapy Drugs for Cancer Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 11. Global Key Players of Radioligand Therapy Drugs for Cancer, Industry Ranking, 2023 vs 2024 vs 2025
Table 12. Global Key Manufacturers of Radioligand Therapy Drugs for Cancer, Manufacturing Sites and Headquarters
Table 13. Global Key Manufacturers of Radioligand Therapy Drugs for Cancer, Product Types and Applications
Table 14. Global Key Manufacturers of Radioligand Therapy Drugs for Cancer, Date of Entry into the Industry
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global Radioligand Therapy Drugs for Cancer Companies by Tier (Tier 1, Tier 2, Tier 3), based on Radioligand Therapy Drugs for Cancer Revenue, 2025
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 18. Global Radioligand Therapy Drugs for Cancer Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 19. Global Radioligand Therapy Drugs for Cancer Sales by Region (K Units), 2021–2026
Table 20. Global Radioligand Therapy Drugs for Cancer Sales Market Share by Region (2021–2026)
Table 21. Global Radioligand Therapy Drugs for Cancer Sales by Region (K Units), 2027–2032
Table 22. Global Radioligand Therapy Drugs for Cancer Sales Market Share by Region (2027–2032)
Table 23. Global Radioligand Therapy Drugs for Cancer Revenue by Region (US$ Million), 2021–2026
Table 24. Global Radioligand Therapy Drugs for Cancer Revenue Market Share by Region (2021–2026)
Table 25. Global Radioligand Therapy Drugs for Cancer Revenue by Region (US$ Million), 2027–2032
Table 26. Global Radioligand Therapy Drugs for Cancer Revenue Market Share by Region (2027–2032)
Table 27. North America Radioligand Therapy Drugs for Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 28. North America Radioligand Therapy Drugs for Cancer Sales by Country (K Units), 2021–2026
Table 29. North America Radioligand Therapy Drugs for Cancer Sales by Country (K Units), 2027–2032
Table 30. North America Radioligand Therapy Drugs for Cancer Revenue by Country (US$ Million), 2021–2026
Table 31. North America Radioligand Therapy Drugs for Cancer Revenue by Country (US$ Million), 2027–2032
Table 32. Europe Radioligand Therapy Drugs for Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 33. Europe Radioligand Therapy Drugs for Cancer Sales by Country (K Units), 2021–2026
Table 34. Europe Radioligand Therapy Drugs for Cancer Sales by Country (K Units), 2027–2032
Table 35. Europe Radioligand Therapy Drugs for Cancer Revenue by Country (US$ Million), 2021–2026
Table 36. Europe Radioligand Therapy Drugs for Cancer Revenue by Country (US$ Million), 2027–2032
Table 37. Asia Pacific Radioligand Therapy Drugs for Cancer Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 38. Asia Pacific Radioligand Therapy Drugs for Cancer Sales by Region (K Units), 2021–2026
Table 39. Asia Pacific Radioligand Therapy Drugs for Cancer Sales by Region (K Units), 2027–2032
Table 40. Asia Pacific Radioligand Therapy Drugs for Cancer Revenue by Region (US$ Million), 2021–2026
Table 41. Asia Pacific Radioligand Therapy Drugs for Cancer Revenue by Region (US$ Million), 2027–2032
Table 42. Latin America Radioligand Therapy Drugs for Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 43. Latin America Radioligand Therapy Drugs for Cancer Sales by Country (K Units), 2021–2026
Table 44. Latin America Radioligand Therapy Drugs for Cancer Sales by Country (K Units), 2027–2032
Table 45. Latin America Radioligand Therapy Drugs for Cancer Revenue by Country (US$ Million), 2021–2026
Table 46. Latin America Radioligand Therapy Drugs for Cancer Revenue by Country (US$ Million), 2027–2032
Table 47. Middle East and Africa Radioligand Therapy Drugs for Cancer Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 48. Middle East and Africa Radioligand Therapy Drugs for Cancer Sales by Country (K Units), 2021–2026
Table 49. Middle East and Africa Radioligand Therapy Drugs for Cancer Sales by Country (K Units), 2027–2032
Table 50. Middle East and Africa Radioligand Therapy Drugs for Cancer Revenue by Country (US$ Million), 2021–2026
Table 51. Middle East and Africa Radioligand Therapy Drugs for Cancer Revenue by Country (US$ Million), 2027–2032
Table 52. Global Radioligand Therapy Drugs for Cancer Sales (K Units) by Type (2021–2026)
Table 53. Global Radioligand Therapy Drugs for Cancer Sales (K Units) by Type (2027–2032)
Table 54. Global Radioligand Therapy Drugs for Cancer Sales Market Share by Type (2021–2026)
Table 55. Global Radioligand Therapy Drugs for Cancer Sales Market Share by Type (2027–2032)
Table 56. Global Radioligand Therapy Drugs for Cancer Revenue (US$ Million) by Type (2021–2026)
Table 57. Global Radioligand Therapy Drugs for Cancer Revenue (US$ Million) by Type (2027–2032)
Table 58. Global Radioligand Therapy Drugs for Cancer Revenue Market Share by Type (2021–2026)
Table 59. Global Radioligand Therapy Drugs for Cancer Revenue Market Share by Type (2027–2032)
Table 60. Global Radioligand Therapy Drugs for Cancer Price (US$/Unit) by Type (2021–2026)
Table 61. Global Radioligand Therapy Drugs for Cancer Price (US$/Unit) by Type (2027–2032)
Table 62. Global Radioligand Therapy Drugs for Cancer Sales (K Units) by Application (2021–2026)
Table 63. Global Radioligand Therapy Drugs for Cancer Sales (K Units) by Application (2027–2032)
Table 64. Global Radioligand Therapy Drugs for Cancer Sales Market Share by Application (2021–2026)
Table 65. Global Radioligand Therapy Drugs for Cancer Sales Market Share by Application (2027–2032)
Table 66. Global Radioligand Therapy Drugs for Cancer Revenue (US$ Million) by Application (2021–2026)
Table 67. Global Radioligand Therapy Drugs for Cancer Revenue (US$ Million) by Application (2027–2032)
Table 68. Global Radioligand Therapy Drugs for Cancer Revenue Market Share by Application (2021–2026)
Table 69. Global Radioligand Therapy Drugs for Cancer Revenue Market Share by Application (2027–2032)
Table 70. Global Radioligand Therapy Drugs for Cancer Price (US$/Unit) by Application (2021–2026)
Table 71. Global Radioligand Therapy Drugs for Cancer Price (US$/Unit) by Application (2027–2032)
Table 72. Novartis Company Information
Table 73. Novartis Description and Business Overview
Table 74. Novartis Radioligand Therapy Drugs for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 75. Novartis Radioligand Therapy Drugs for Cancer Product
Table 76. Novartis Recent Developments/Updates
Table 77. Bayer Company Information
Table 78. Bayer Description and Business Overview
Table 79. Bayer Radioligand Therapy Drugs for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 80. Bayer Radioligand Therapy Drugs for Cancer Product
Table 81. Bayer Recent Developments/Updates
Table 82. Progenics (Lantheus) Company Information
Table 83. Progenics (Lantheus) Description and Business Overview
Table 84. Progenics (Lantheus) Radioligand Therapy Drugs for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 85. Progenics (Lantheus) Radioligand Therapy Drugs for Cancer Product
Table 86. Progenics (Lantheus) Recent Developments/Updates
Table 87. Acrotech Biopharma Inc Company Information
Table 88. Acrotech Biopharma Inc Description and Business Overview
Table 89. Acrotech Biopharma Inc Radioligand Therapy Drugs for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 90. Acrotech Biopharma Inc Radioligand Therapy Drugs for Cancer Product
Table 91. Acrotech Biopharma Inc Recent Developments/Updates
Table 92. BMS Company Information
Table 93. BMS Description and Business Overview
Table 94. BMS Radioligand Therapy Drugs for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 95. BMS Radioligand Therapy Drugs for Cancer Product
Table 96. BMS Recent Developments/Updates
Table 97. AstraZeneca Company Information
Table 98. AstraZeneca Description and Business Overview
Table 99. AstraZeneca Radioligand Therapy Drugs for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 100. AstraZeneca Radioligand Therapy Drugs for Cancer Product
Table 101. AstraZeneca Recent Developments/Updates
Table 102. Eli Lilly Company Information
Table 103. Eli Lilly Description and Business Overview
Table 104. Eli Lilly Radioligand Therapy Drugs for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 105. Eli Lilly Radioligand Therapy Drugs for Cancer Product
Table 106. Eli Lilly Recent Developments/Updates
Table 107. Convergent Therapeutics Company Information
Table 108. Convergent Therapeutics Description and Business Overview
Table 109. Convergent Therapeutics Radioligand Therapy Drugs for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 110. Convergent Therapeutics Radioligand Therapy Drugs for Cancer Product
Table 111. Convergent Therapeutics Recent Developments/Updates
Table 112. Grand Pharmaceutical Company Information
Table 113. Grand Pharmaceutical Description and Business Overview
Table 114. Grand Pharmaceutical Radioligand Therapy Drugs for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 115. Grand Pharmaceutical Radioligand Therapy Drugs for Cancer Product
Table 116. Grand Pharmaceutical Recent Developments/Updates
Table 117. Bivision Pharmaceuticals Company Information
Table 118. Bivision Pharmaceuticals Description and Business Overview
Table 119. Bivision Pharmaceuticals Radioligand Therapy Drugs for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 120. Bivision Pharmaceuticals Radioligand Therapy Drugs for Cancer Product
Table 121. Bivision Pharmaceuticals Recent Developments/Updates
Table 122. Jiangsu Hengrui Company Information
Table 123. Jiangsu Hengrui Description and Business Overview
Table 124. Jiangsu Hengrui Radioligand Therapy Drugs for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 125. Jiangsu Hengrui Radioligand Therapy Drugs for Cancer Product
Table 126. Jiangsu Hengrui Recent Developments/Updates
Table 127. Key Raw Materials Lists
Table 128. Raw Materials Key Suppliers Lists
Table 129. Radioligand Therapy Drugs for Cancer Distributors List
Table 130. Radioligand Therapy Drugs for Cancer Customers List
Table 131. Radioligand Therapy Drugs for Cancer Market Trends
Table 132. Radioligand Therapy Drugs for Cancer Market Drivers
Table 133. Radioligand Therapy Drugs for Cancer Market Challenges
Table 134. Radioligand Therapy Drugs for Cancer Market Restraints
Table 135. Research Programs/Design for This Report
Table 136. Key Data Information from Secondary Sources
Table 137. Key Data Information from Primary Sources
Table 138. Authors List of This Report
List of Figures
Figure 1. Product Picture of Radioligand Therapy Drugs for Cancer
Figure 2. Global Radioligand Therapy Drugs for Cancer Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Radioligand Therapy Drugs for Cancer Market Share by Type: 2025 & 2032
Figure 4. Lutetium 177 Product Picture
Figure 5. Radium 223 Product Picture
Figure 6. Acetium 225 Product Picture
Figure 7. Others Product Picture
Figure 8. Global Radioligand Therapy Drugs for Cancer Market Value by Targeted Ligands (US$ Million), 2021–2032
Figure 9. Global Radioligand Therapy Drugs for Cancer Market Share by Targeted Ligands: 2025 vs 2032
Figure 10. by Peptides Product Picture
Figure 11. Small Molecules Product Picture
Figure 12. Antibodies Product Picture
Figure 13. Others Product Picture
Figure 14. Global Radioligand Therapy Drugs for Cancer Market Value by Radionuclides (US$ Million), 2021–2032
Figure 15. Global Radioligand Therapy Drugs for Cancer Market Share by Radionuclides: 2025 vs 2032
Figure 16. β-emitters Product Picture
Figure 17. α-emitters Product Picture
Figure 18. Others Product Picture
Figure 19. Global Radioligand Therapy Drugs for Cancer Market Value by Application (US$ Million), 2021–2032
Figure 20. Global Radioligand Therapy Drugs for Cancer Market Share by Application: 2025 & 2032
Figure 21. Prostate Cancer
Figure 22. Liver Cancer
Figure 23. Breast Cancer
Figure 24. Lung Cancer
Figure 25. Others
Figure 26. Global Radioligand Therapy Drugs for Cancer Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 27. Global Radioligand Therapy Drugs for Cancer Market Size (US$ Million), 2021–2032
Figure 28. Global Radioligand Therapy Drugs for Cancer Sales (K Units), 2021–2032
Figure 29. Global Radioligand Therapy Drugs for Cancer Average Price (US$/Unit), 2021–2032
Figure 30. Radioligand Therapy Drugs for Cancer Report Years Considered
Figure 31. Radioligand Therapy Drugs for Cancer Sales Share by Manufacturers in 2025
Figure 32. Global Radioligand Therapy Drugs for Cancer Revenue Share by Manufacturers in 2025
Figure 33. Top 5 and Top 10 Global Radioligand Therapy Drugs for Cancer Players: Market Share by Revenue in Radioligand Therapy Drugs for Cancer in 2025
Figure 34. Radioligand Therapy Drugs for Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 35. Global Radioligand Therapy Drugs for Cancer Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 36. North America Radioligand Therapy Drugs for Cancer Sales Market Share by Country (2021–2032)
Figure 37. North America Radioligand Therapy Drugs for Cancer Revenue Market Share by Country (2021–2032)
Figure 38. United States Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. Canada Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Europe Radioligand Therapy Drugs for Cancer Sales Market Share by Country (2021–2032)
Figure 41. Europe Radioligand Therapy Drugs for Cancer Revenue Market Share by Country (2021–2032)
Figure 42. Germany Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. France Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. U.K. Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Italy Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Russia Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Asia Pacific Radioligand Therapy Drugs for Cancer Sales Market Share by Region (2021–2032)
Figure 48. Asia Pacific Radioligand Therapy Drugs for Cancer Revenue Market Share by Region (2021–2032)
Figure 49. China Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Japan Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. South Korea Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. India Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. Australia Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. China Taiwan Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. Southeast Asia Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 56. Latin America Radioligand Therapy Drugs for Cancer Sales Market Share by Country (2021–2032)
Figure 57. Latin America Radioligand Therapy Drugs for Cancer Revenue Market Share by Country (2021–2032)
Figure 58. Mexico Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 59. Brazil Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 60. Argentina Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 61. Colombia Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 62. Middle East and Africa Radioligand Therapy Drugs for Cancer Sales Market Share by Country (2021–2032)
Figure 63. Middle East and Africa Radioligand Therapy Drugs for Cancer Revenue Market Share by Country (2021–2032)
Figure 64. Turkey Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 65. Saudi Arabia Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 66. UAE Radioligand Therapy Drugs for Cancer Revenue Growth Rate (US$ Million), 2021–2032
Figure 67. Global Sales Market Share of Radioligand Therapy Drugs for Cancer by Type (2021–2032)
Figure 68. Global Revenue Market Share of Radioligand Therapy Drugs for Cancer by Type (2021–2032)
Figure 69. Global Radioligand Therapy Drugs for Cancer Price (US$/Unit) by Type (2021–2032)
Figure 70. Global Sales Market Share of Radioligand Therapy Drugs for Cancer by Application (2021–2032)
Figure 71. Global Revenue Market Share of Radioligand Therapy Drugs for Cancer by Application (2021–2032)
Figure 72. Global Radioligand Therapy Drugs for Cancer Price (US$/Unit) by Application (2021–2032)
Figure 73. Radioligand Therapy Drugs for Cancer Value Chain
Figure 74. Channels of Distribution (Direct Vs Distribution)
Figure 75. Bottom-up and Top-down Approaches for This Report
Figure 76. Data Triangulation
Figure 77. Key Executives Interviewed
